These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 11333991

  • 1. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
    Exner DV, Dries DL, Domanski MJ, Cohn JN.
    N Engl J Med; 2001 May 03; 344(18):1351-7. PubMed ID: 11333991
    [Abstract] [Full Text] [Related]

  • 2. Racial differences in the outcome of left ventricular dysfunction.
    Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ.
    N Engl J Med; 1999 Feb 25; 340(8):609-16. PubMed ID: 10029645
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.
    Dries DL, Strong MH, Cooper RS, Drazner MH.
    J Am Coll Cardiol; 2002 Jul 17; 40(2):311-7. PubMed ID: 12106937
    [Abstract] [Full Text] [Related]

  • 4. The impact of race on response to RAAS inhibition.
    Wallace TW, Drazner MH.
    Curr Heart Fail Rep; 2005 Aug 17; 2(2):72-7. PubMed ID: 16036054
    [Abstract] [Full Text] [Related]

  • 5. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
    Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J.
    Am Heart J; 1999 Nov 17; 138(5 Pt 1):849-55. PubMed ID: 10539815
    [Abstract] [Full Text] [Related]

  • 6. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
    Carson P, Ziesche S, Johnson G, Cohn JN.
    J Card Fail; 1999 Sep 17; 5(3):178-87. PubMed ID: 10496190
    [Abstract] [Full Text] [Related]

  • 7. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
    Böhm M, Pogue J, Kindermann I, Pöss J, Koon T, Yusuf S.
    Eur J Heart Fail; 2014 Mar 17; 16(3):325-33. PubMed ID: 24464788
    [Abstract] [Full Text] [Related]

  • 8. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
    Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI.
    Lancet; 2003 May 31; 361(9372):1843-8. PubMed ID: 12788569
    [Abstract] [Full Text] [Related]

  • 9. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
    Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S.
    Circulation; 1996 Aug 15; 94(4):690-7. PubMed ID: 8772689
    [Abstract] [Full Text] [Related]

  • 10. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
    Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D.
    Circulation; 1992 Aug 15; 86(2):431-8. PubMed ID: 1638712
    [Abstract] [Full Text] [Related]

  • 11. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
    Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC, Studies Of Left Ventricular Dysfunction.
    Circulation; 2003 Mar 11; 107(9):1291-6. PubMed ID: 12628950
    [Abstract] [Full Text] [Related]

  • 12. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
    SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN.
    N Engl J Med; 1992 Sep 03; 327(10):685-91. PubMed ID: 1463530
    [Abstract] [Full Text] [Related]

  • 13. Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
    Gregory DD, Sarnak MJ, Konstam MA, Pereira B, Salem D.
    Am J Cardiol; 2003 Dec 01; 92(11):1300-5. PubMed ID: 14636907
    [Abstract] [Full Text] [Related]

  • 14. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
    Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D.
    Circulation; 1993 Nov 01; 88(5 Pt 1):2277-83. PubMed ID: 8222122
    [Abstract] [Full Text] [Related]

  • 15. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
    Parker AB, Yusuf S, Naylor CD.
    Am Heart J; 2002 Dec 01; 144(6):941-7. PubMed ID: 12486418
    [Abstract] [Full Text] [Related]

  • 16. Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction.
    Patten RD, Kronenberg MW, Benedict CR, Udelson JE, Kinan D, Stewart D, Yusuf S, Smith JJ, Kilcoyne L, Dolan N, Edens TR, Metherall J, Konstam MA.
    Am Heart J; 1997 Jul 01; 134(1):37-43. PubMed ID: 9266781
    [Abstract] [Full Text] [Related]

  • 17. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
    McCallum W, Tighiouart H, Ku E, Salem D, Sarnak MJ.
    Am J Kidney Dis; 2020 Jan 01; 75(1):21-29. PubMed ID: 31303349
    [Abstract] [Full Text] [Related]

  • 18. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators.
    Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, Mottard I, Woods P, Konstam MA, Yusuf S.
    Am J Cardiol; 1996 Oct 15; 78(8):890-5. PubMed ID: 8888661
    [Abstract] [Full Text] [Related]

  • 19. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, Desai AS, Rouleau JL, Swedberg K, Fonarow GC.
    JAMA Cardiol; 2018 Dec 01; 3(12):1226-1231. PubMed ID: 30484837
    [Abstract] [Full Text] [Related]

  • 20. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.
    Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA.
    J Am Coll Cardiol; 1998 Feb 01; 31(2):419-25. PubMed ID: 9462588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.